Modus Therapeutics Holding AB (MODTX) AI Stock Analysis

Modus Therapeutics Holding AB

(Nasdaq OMX AB:MODTX)

Select Model

Rating:40Underperform

Price Target:SEK 0.17▼(-7.61% Downside)

Action:reiterated

Date:10/21/26

The score is held down primarily by the financial profile: Modus Therapeutics generates no revenue, burns roughly SEK 18 million of cash annually, and holds only about SEK 10 million of equity, pointing to a likely near-term capital raise and shareholder dilution. A debt-free balance sheet and stable, controlled cost base are modest positives. Technically, the shares trade well below all major moving averages with negative MACD, though extremely low RSI and Stochastic readings indicate deeply oversold conditions that could permit short-term rebounds. With negative earnings and no dividend, valuation offers no support, leaving the investment case dependent entirely on clinical progress and access to funding.

Positive Factors

Debt-Free Balance SheetThe absence of debt reduces interest obligations and near-term refinancing pressure, giving Modus greater financial flexibility while it advances development programs. This conservative capital structure can help preserve strategic options during clinical execution and future financing decisions.

Negative Factors

Pre-Revenue Business ModelThe absence of product revenue means Modus has not yet established a commercial income stream to fund operations or validate recurring demand. Its financial outlook therefore remains dependent on successful development, approval, partnering, or other future monetization milestones.

Modus Therapeutics Holding AB (MODTX) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 31.19M
Dividend Yield: ―
Average Volume (3M): 1.17M
Price to Earnings (P/E): -1.0
Beta (1Y): 2.13
Revenue Growth: ―
EPS Growth: 0.22%
Country: Sweden
Employees: 2
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Modus Therapeutics Holding AB Business Overview & Revenue Model

Company Description

Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated w...

How the Company Makes Money

Modus Therapeutics is a clinical-stage biotechnology company and, based on publicly available information, it does not appear to generate recurring commercial product revenue. Its business model is primarily to fund and advance its drug development p...

Modus Therapeutics Holding AB Financial Statement Overview

Summary

Modus Therapeutics is a pre-revenue, clinical-stage biotech with no sales recorded from 2021 through the latest twelve months and persistent net losses of roughly SEK 15–21 million per year (SEK 17.6 million in the TTM period). Operating cash flow was approximately SEK -18.6 million, with free cash flow equally negative given the absence of capital spending. The balance sheet offers partial offset: debt has been zero since 2023 and equity has been rebuilt to about SEK 10.2 million against SEK 13.3 million of total assets. However, that equity base is smaller than the annual burn, implying under a year of self-funded runway and a high probability of further dilutive capital raises. Return on equity remains deeply negative (about -177%), and funding volatility across 2023–2025 underlines the reliance on external capital.

Income Statement

7Very Negative

Balance Sheet

38Negative

Cash Flow

9Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0
EBITDA	-17.47M	-18.17M	-15.84M	2,000	0	-20.69M
Net Income	-17.59M	-18.54M	-15.54M	-17.90M	-18.32M	-20.69M
Balance Sheet
Total Assets	13.28M	12.69M	4.88M	20.04M	11.27M	21.19M
Cash, Cash Equivalents and Short-Term Investments	12.49M	11.37M	4.38M	19.06M	10.42M	20.65M
Total Debt	0	0	0	0	11.50M	0
Total Liabilities	3.04M	3.62M	2.75M	2.36M	13.86M	5.46M
Stockholders Equity	10.24M	9.07M	2.14M	17.68M	-2.58M	15.73M
Cash Flow
Free Cash Flow	-18.57M	-18.07M	-14.68M	-16.68M	-21.72M	-16.08M
Operating Cash Flow	-18.57M	-18.07M	-14.68M	-16.68M	-21.72M	-16.08M
Investing Cash Flow	0	0	0	0	0	-50.00K
Financing Cash Flow	29.16M	25.07M	0	25.32M	11.50M	29.43M

Modus Therapeutics Holding AB Technical Analysis

Technical Analysis SentimentNegative

Last Price0.18

Price Trends

50DMA0.35Negative

100DMA0.37Negative

200DMA0.36Negative

Market Momentum

MACD-0.06Positive

RSI23.08Positive

STOCH23.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:MODTX, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.35, and below the 200-day MA of 0.36, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 23.08 is Positive, neither overbought nor oversold. The STOCH value of 23.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:MODTX.

Modus Therapeutics Holding AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:MODTX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CANTA	70Outperform	SEK 451.68M	2.35	63.09%	―	―	―
SE:HNSA	55Neutral	SEK 4.00B	-5.00	―	―	-3.57%	8.84%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:BINV	43Neutral	SEK 357.32M	-0.73	-128.54%	―	-83.67%	-50.29%
SE:IMMU	43Neutral	SEK 348.89M	-3.07	-18.05%	―	―	15.97%
SE:MODTX	40Underperform	SEK 31.19M	-1.02	-177.45%	―	―	0.22%
SE:VICO	39Underperform	SEK 2.73B	-5.05	-53.71%	―	-48.40%	-1.06%

* Healthcare Sector Average

Performance Comparison

SE:MODTX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:MODTX	Modus Therapeutics Holding AB	0.18	-0.22	-54.68%
SE:HNSA	Hansa Biopharma	39.34	8.34	26.90%
SE:BINV	BioInvent International AB	5.43	-28.47	-83.98%
SE:VICO	Vicore Pharma Holding AB	9.70	-1.18	-10.85%
SE:IMMU	Immunicum AB	5.50	-1.89	-25.58%
SE:CANTA	Cantargia AB	1.60	-1.97	-55.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 21, 2026

Modus Therapeutics Holding AB AI Stock Analysis